Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

Previous results from this trial showed longer overall survival after treatment with nivolumab plus ipilimumab or with nivolumab monotherapy than with ipilimumab monotherapy in patients with ...

Nivolumab, alone or with ipilimumab, significantly improved 10-year overall and melanoma-specific survival vs ipilimumab ...

Immunotherapy, which works by enabling the body’s immune system to recognise and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large ...

Melanoma is a type of skin cancer that starts when pigment cells in the skin grow uncontrollably, rising for the last 30 ...

A 10-year follow-up of the CheckMate 067 trial shows that around half of metastatic melanoma patients treated with nivolumab and ipilimumab are cancer-free after a decade. The study confirms long-term ...

When it comes to surreal and experimental stop-motion animations, one of the most recognisable filmmakers who specialise in ...

Long-term data from a landmark international trial show about half of patients with metastatic melanoma treated with a combination of immune checkpoint inhibitors survive cancer-free for 10 years or ...

During a Case-Based Roundtable® event, Hussein A. Tawbi, MD, PhD, and participants look at benefits of nivolumab combinations ...